Stryker Acquires Amplitude Vascular Systems to Expand PV Portfolio

Stryker, a global leader in medical technologies, has signed a definitive agreement to acquire Amplitude Vascular Systems, Inc. (AVS), a privately held company specializing in next-generation intravascular lithotripsy (IVL) technology. This acquisition aims to bolster Stryker’s Peripheral Vascular (PV) portfolio by incorporating AVS’s innovative revascularization platform designed to treat calcified peripheral arterial disease.

While the financial terms of the deal remain undisclosed, the acquisition is expected to complement Stryker’s existing PV offerings once the IVL platform receives regulatory clearance in applicable markets. The integration of this technology aligns with Stryker’s strategic objective to expand its presence in arterial disease treatment and enhance patient outcomes.

Stryker, listed on the NYSE under the ticker SYK, is a prominent medical technology company known for its broad portfolio of products across orthopedics, surgical equipment, and vascular devices. Amplitude Vascular Systems is a privately held medical technology firm focused on developing advanced IVL platforms that address the challenges of calcified peripheral arterial disease, a condition that complicates revascularization procedures.

The acquisition provides Stryker with access to AVS’s next-generation IVL technology, which uses sonic pressure waves to fracture calcified plaque within peripheral arteries, facilitating improved blood flow. This technology is expected to expand treatment options for patients and enhance Stryker’s competitive positioning in the peripheral vascular market.

Strategically, the deal offers multiple synergies. Revenue opportunities include cross-selling AVS’s IVL platform alongside Stryker’s existing PV products, expanding the addressable market, and accelerating commercialization through Stryker’s global sales network. Cost synergies are anticipated from shared research and development efforts, consolidated manufacturing, and streamlined regulatory processes. Operationally, Stryker plans to integrate the IVL technology into its product portfolio while leveraging established distribution channels and clinical support infrastructure.

The peripheral vascular device market is experiencing increased innovation and consolidation, driven by rising prevalence of arterial diseases and demand for minimally invasive treatments. Stryker’s acquisition of AVS positions the company to capitalize on these trends and respond to competitive pressures, as rivals may pursue similar technologies or partnerships to maintain market share.

Financial details such as deal value, multiples, and funding sources have not been disclosed. The transaction is subject to customary regulatory approvals and is expected to close following clearance of the IVL platform in key markets including North America, Europe, and Asia-Pacific.

Post-acquisition, Stryker will focus on integrating AVS’s technology with its existing PV offerings, aligning clinical and sales teams, and navigating regulatory pathways to expedite market entry. The company anticipates that this acquisition will drive long-term growth by broadening treatment capabilities and enhancing its leadership in peripheral arterial disease management.

Overall, the acquisition reflects Stryker’s commitment to innovation and portfolio expansion in the medical technology sector, reinforcing its position in the evolving peripheral vascular market.